Research programme: thrombopoietin receptor agonists - Chugai

Drug Profile

Research programme: thrombopoietin receptor agonists - Chugai

Alternative Names: huVB22B; Thrombopoietin receptor agonists research programme - Chugai

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical
  • Class Antibodies; Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Thrombocytopenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombocytopenia in Japan
  • 09 Dec 2008 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Thrombocytopenia presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008)
  • 09 Feb 2005 Preclinical trials in Thrombocytopenia in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top